Effectiveness of Warfarin Among Patients with Cancer

Overview

Journal J Gen Intern Med

Publisher Springer

Specialty General Medicine

Date 2007 May 4

PMID 17476542

Citations 19

Authors

Adam J Rose

Jeff P Sharman

Al Ozonoff

Lori E Henault

Elaine M Hylek

Affiliations

Soon will be listed here.

Abstract

Background: Among patients treated with warfarin for venous thromboembolism (VTE), cancer patients have more thrombotic and hemorrhagic events than patients without cancer. Is this also the case when cancer patients are anticoagulated for other indications?

Objective: The objective of the study is to evaluate the effectiveness of warfarin, given for any indication, among patients with cancer in a community setting.

Methods: We identified patients with cancer from a larger prospective cohort of 6,761 patients from 101 clinical sites in the United States, matched to controls without cancer. The proportion of time spent in the therapeutic range, international normalized ration (INR) variability, and the rate of thromboembolic and major hemorrhagic events were compared between the two groups.

Results: Ninety-five patients undergoing treatment for cancer were matched to 283 patients without cancer. The cancer group spent less time in the target INR range (54 vs 66%, P < .001) and had more variable INR values (standard deviation around the mean INR value 1.30 vs 0.71, P < .001). There were more thrombotic events in the cancer group than in the control group (5 vs 0 events, P < .001). These analyses were repeated after excluding all of the patients anticoagulated for VTE; the results were unchanged.

Conclusions: Compared to matched controls, cancer patients receiving warfarin spend less time in the target INR range, have more variable INR values, and have more thrombotic events. These effects are not dependent on whether the patient is anticoagulated for VTE or another indication.

Citing Articles

Thromboembolism in Patients with Cancer: A Practical Guide to Recurrent Events.

Kozhukhov S, Dovganych N Rev Cardiovasc Med. 2024; 25(11):406.

PMID: 39618864 PMC: 11607493. DOI: 10.31083/j.rcm2511406.

Acute reperfusion treatment and secondary prevention of cancer-related stroke: comprehensive overview and proposal of clinical algorithm.

Aloizou A, Palaiodimou L, Aloizou D, Dardiotis E, Gold R, Tsivgoulis G Ther Adv Neurol Disord. 2023; 16:17562864231180717.

PMID: 37342814 PMC: 10278431. DOI: 10.1177/17562864231180717.

Superiority of Direct Oral Anticoagulants over Vitamin K Antagonists in Oncological Patients with Atrial Fibrillation: Analysis of Efficacy and Safety Outcomes.

Parrini I, Luca F, Rao C, Parise G, Micali L, Musumeci G J Clin Med. 2022; 11(19).

PMID: 36233581 PMC: 9572823. DOI: 10.3390/jcm11195712.

Atrial fibrillation in older adults with cancer.

Kumar M, Lopetegui-Lia N, Al Malouf C, Almnajam M, Coll P, Kim A J Geriatr Cardiol. 2022; 19(1):1-8.

PMID: 35233218 PMC: 8832038. DOI: 10.11909/j.issn.1671-5411.2022.01.001.

Direct Oral Anticoagulants Are Associated with Superior Survival Outcomes than Warfarin in Patients with Head and Neck Cancers.

Lee C, Chen W, Wee Y, Wang C, Chen W, Chiu T Cancers (Basel). 2022; 14(3).

PMID: 35158969 PMC: 8833638. DOI: 10.3390/cancers14030703.

References

White R, Beyth R, Zhou H, Romano P . Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999; 107(5):414-24. DOI: 10.1016/s0002-9343(99)00267-3. View

Sconce E, Avery P, Wynne H, Kamali F . Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood. 2006; 109(6):2419-23. DOI: 10.1182/blood-2006-09-049262. View

Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, DAngelo A . A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 2000; 84(5):805-10. View

Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal A . Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001; 98(5):1614-5. DOI: 10.1182/blood.v98.5.1614. View

Hylek E, Regan S, Go A, Hughes R, Singer D, Skates S . Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 2001; 135(6):393-400. DOI: 10.7326/0003-4819-135-6-200109180-00008. View

Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P . Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002; 162(15):1729-35. DOI: 10.1001/archinte.162.15.1729. View

Prandoni P, Lensing A, Piccioli A, Bernardi E, Simioni P, Girolami B . Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100(10):3484-8. DOI: 10.1182/blood-2002-01-0108. View

Lee A, Levine M . Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003; 107(23 Suppl 1):I17-21. DOI: 10.1161/01.CIR.0000078466.72504.AC. View

Lee A, Levine M, Baker R, Bowden C, Kakkar A, Prins M . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2):146-53. DOI: 10.1056/NEJMoa025313. View

10.

Hylek E . Trends in anticoagulation management across community-based practices in the United States: the Anticoagulation Consortium to Improve Outcomes Nationally (ACTION) study. J Thromb Thrombolysis. 2004; 16(1-2):83-6. DOI: 10.1023/B:THRO.0000014600.21367.7b. View

11.

Elting L, Escalante C, Cooksley C, Avritscher E, Kurtin D, Hamblin L . Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004; 164(15):1653-61. DOI: 10.1001/archinte.164.15.1653. View

12.

Buller H, Agnelli G, Hull R, Hyers T, Prins M, Raskob G . Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl):401S-428S. DOI: 10.1378/chest.126.3_suppl.401S. View

13.

Levine M, Gent M, Hirsh J, Arnold A, Goodyear M, Hryniuk W . The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988; 318(7):404-7. DOI: 10.1056/NEJM198802183180703. View

14.

Landefeld C, Goldman L . Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989; 87(2):144-52. DOI: 10.1016/s0002-9343(89)80689-8. View

15.

Kent D, Vermes D, McDonell M, Henikoff J, Fihn S . A model for planning optimal follow-up for outpatients on warfarin anticoagulation. Warfarin Optimal Outpatient Follow-up Study Group. Med Decis Making. 1992; 12(2):132-41. DOI: 10.1177/0272989X9201200206. View

16.

Rosendaal F, Cannegieter S, van der Meer F, Briet E . A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69(3):236-9. View

17.

Sorano G, Biondi G, Conti M, Mameli G, Licheri D, Marongiu F . Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal. Haemostasis. 1993; 23(2):77-82. DOI: 10.1159/000216857. View

18.

Gitter M, Jaeger T, Petterson T, Gersh B, Silverstein M . Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995; 70(8):725-33. DOI: 10.4065/70.8.725. View

19.

Bona R, Sivjee K, Hickey A, Wallace D, Wajcs S . The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost. 1995; 74(4):1055-8. View

20.

Fihn S, Callahan C, Martin D, McDonell M, Henikoff J, White R . The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med. 1996; 124(11):970-9. DOI: 10.7326/0003-4819-124-11-199606010-00004. View